KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Gains from Investment Securities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Gains from Investment Securities for 15 consecutive years, with -$15000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 110.07% to -$15000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $410000.0, a 126.81% increase, with the full-year FY2025 number at $410000.0, up 126.81% from a year prior.
  • Gains from Investment Securities was -$15000.0 for Q4 2025 at Halozyme Therapeutics, up from -$307000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.3 million in Q1 2025 to a low of -$2.6 million in Q2 2025.
  • A 5-year average of -$139625.0 and a median of $67000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 888.75% in 2023, then plummeted 443.42% in 2024.
  • Halozyme Therapeutics' Gains from Investment Securities stood at -$693000.0 in 2021, then plummeted by 58.59% to -$1.1 million in 2022, then crashed by 65.79% to -$1.8 million in 2023, then soared by 108.18% to $149000.0 in 2024, then plummeted by 110.07% to -$15000.0 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Gains from Investment Securities are -$15000.0 (Q4 2025), -$307000.0 (Q3 2025), and -$2.6 million (Q2 2025).